A Safety and Efficacy Study of Two Dose Levels of Taliglucerase Alfa in Pediatric Subjects With Gaucher Disease

Inclusion Criteria: * Males and females 2 to \<18 years old. * Diagnosis of Gaucher disease with leukocyte acid β-glucosidase activity ≤30% of the mean of the reference range for healthy subjects. * Subjects who have not received enzyme replacement therapy (ERT) in the past or who have not received ERT in the past 12 months and have a negative anti-glucocerebrosidase antibody assay. * Subjects who have not received substrate reduction therapy (SRT) in the past 12 months. * Subjects whose clinical condition, in the opinion of the investigator, requires treatment with enzyme replacement therapy (ERT). Exclusion Criteria: * Currently taking another investigational drug for any condition. * Presence of neurological signs and symptoms characteristic of Gaucher disease with complex neuronopathic features other than longstanding oculomotor gaze palsy. * Presence of unresolved anemia due to iron, folic acid, or vitamin B12 deficiency * Previous hypersensitivity reaction to Cerezyme® (imiglucerase) or Ceredase® (alglucerase). * History of allergy to carrots. * Presence of HIV, HBsAg or hepatitis C infections. * Subject's parent(s) or legal guardian(s) are unable to understand the nature, scope and possible consequences of the study. * Presence of any medical, emotional, behavioral or psychological condition that in the judgment of the Investigator would interfere with the subject's compliance with the requirements of the study.